Discussions concerning the FY 2025 and FY 2026 appropriations bills; provisions related to the FDA regulation of tobacco.
Implementation of P.L. 111-31, the Tobacco Control Act; Issues surrounding FDA PMTA and MRTP compliance policies; Issues surrounding tobacco harm reduction; Issues surrounding efforts to prevent youth access to tobacco products; Discussions in support of the regulation of products containing synthetic nicotine and disposable e-cigarettes; Issues surrounding increased scrutiny on FDA/CTP for delayed enforcement; Issues surrounding CBP resources for interdicting massive influx & mislabeling illicit vapes; Issues surrounding retail inspections enforcement limitation; Issues surrounding implementation of P.L. 111-31, the Tobacco Control Act; NPRM for Docket No. FDA-2021-N-1349: Tobacco Product Standard for Menthol in Cigarettes; January 2025 Proposed Rule: Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products; Issues surrounding efforts to prevent youth access to tobacco products; Discussions regarding federal excise taxes and the taxation of tobacco products; Discussions regarding FDA enforcement of flavored disposable e-cigarettes and PMTA transparency.
Issues surrounding prevention of illicit tobacco, patents, tariffs, duty and customs, Free Trade Agreements (FTAs); HR 1, THE ONE BIG BEAUTIFUL BILL
S. 464, No Tax Subsidies for E-Cigarette and Tobacco Ads Act; S. 2929/H.R. 5715, Tobacco Tax Equity Act; Issues surrounding Internal Revenue Code 420; Discussions concerning the tax rate on corporate stock buybacks and U.S. multinationals foreign earnings; Discussions concerning draft legislation to amend corporate tax rates and federal excise taxes/duties on tobacco products; Discussions concerning a retaliatory tax on international companies from countries that adopt extraterritorial tax schemes; Issues surrounding taxation of tobacco products.